Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | CFTR | P13569 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195076 | 0.93 | GAA (0.57) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL1884944 | 0.85 | GAA (0.64) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL195591 | 0.85 | KDM4E (0.61) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL28149249 | 0.84 | KDM4E (0.56) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL9248547 | 0.84 | ALPL (0.50) | ABL1ALDH1A1GAAHPGDMAPT | |
| SCHEMBL12683792 | 0.84 | HPGD (0.51) | ABL1ALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL7762378 | 0.84 | ABL1 (0.61) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL2900514 | 0.84 | KDM4E (0.59) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL23539774 | 0.84 | GAA (0.48) | ABL1KDM4EALDH1A1GAACFTR | |
| SCHEMBL29476391 | 0.84 | GAA (0.48) | ABL1KDM4EALDH1A1GAACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250197377-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4380924-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117794902-A | Novel pharmaceutically acceptable salts and polymorphic forms of ErbB and BTK inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023011358-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-12 | — | — | US | disclosed |
| WO-2019149164-A1 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018170275-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2017192304-A1 | ARYLCARBOXAMIDES AND USES THEREOF | INCEPTION 1, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | OPRD1, OPRM1, OPRK1 | ABL1 2514/4885KDM4E 1278/4885ALDH1A1 577/4885 |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | OPRD1, OPRM1, OPRK1 | ABL1 2514/4885KDM4E 1278/4885ALDH1A1 577/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | ABL1 1822/4885KDM4E 2636/4885ALDH1A1 2933/4885 |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ABL1 8/4885KDM4E 1687/4885ALDH1A1 4856/4885 |
| US-20250197377-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHIC FORMS OF AN ERBB AND BTK INHIBITOR | BTK, ERBB2, ERBB3 | ABL1 9/4885KDM4E 2230/4885ALDH1A1 4277/4885 |
| US-11007198-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | ABL1 8/4885KDM4E 1687/4885ALDH1A1 4856/4885 |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ABL1 8/4885KDM4E 1687/4885ALDH1A1 4856/4885 |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, KMT5A, CDKL1 | ABL1 864/4885KDM4E 126/4885ALDH1A1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.